Abbott Laboratories Shares Decline Following Lowered 2026 Growth Outlook
Abbott Laboratories (ABT) saw its stock price slip in premarket trading following the release of its Q3 results. While the company reported strong quarterly performance with revenue reaching $13.0 billion—a 14.5% year-over-year increase that exceeded analyst estimates—the market reacted negatively to a revised, lower growth outlook for 2026. The downward revision comes as the MedTech giant moves forward with strategic plans to separate its nutrition business. Investors appear focused on the long-term guidance adjustments despite the immediate beat in quarterly revenue figures.
Tickers: $ABT
Topics: business restructuring earnings report guidance downgrade revenue growth
Read the full article at Seeking Alpha
Part of the story Abbott Announces Nutrition Business Spin-off to Focus on High-Margin Medical Technologies (5 articles)